ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

US Could Lose Leadership In Research If NIH Budget Is Cut, ASCO President Says

June 2, 1995

Abigail Alliance says statisticians usurped control of oncology. Milken’s optimism fuels the movement.

August 5, 2005

Richard Bloch, advocate for patient information services, dead at 78.

July 30, 2004

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

In Brief: SBA Writing Guidelines to Implement Act Giving 1.25 Percent Of R&D Budget To Small Business

July 23, 1982

DCT Advisors Approve Five Trials For High Priority Status

April 7, 1995